Mutations in gyrA and gyrB genes among strains of Gram-negative bacilli isolated from Chilean hospitals and their relation with resistance to fluoroquinolones;Mutaciones en genes gyrA y gyrB en cepas de bacilos Gram negativos aisladas en hospitales chilenos y su relación con la resistencia a fluoroquinolonas

Revista Medica de Chile

Volumn 135, Issue 9, 2007, Pages 1103-1110

  De La Fuente C, Mery ^a   Dauros S, Priscila ^a   Bello T, Helia ^a   Domínguez Y, Mariana ^a,b   Mella M, Sergio ^a   Sepúlveda A, Marcela ^a,b   Zemelman Z, Raúl ^b   González R, Gerardo ^a  

^a UNIVERSITY OF CONCEPCIÓN   (Chile)

^b UNIVERSIDAD SAN SEBASTIÁN   (Chile)

Author keywords

DNA gyrase; Fluoroquinolones; gyrA gene product; gyrB gene product

Indexed keywords

EID: 36349008669     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. RUIZ J. Mechanisms of resistance to quinolones: target altertions, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother 2003; 51: 1109-17.
2. TRAN J, JACOBY G, HOOPER D. Interaction of the Plasmid-Encoded Quinolone Resistance Protein Qnr with Escherichia coli DNA Gyrase. Antimicrob Agents Chemother 2005; 49: 118-25.
3. YOSHIDA H, BOGAKI M, NAKAMURA M, NAKAMURA S. Quinolone resistant-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother 1990; 34: 1271-2.
4. EVERETT M, FANG Y, RICCI V, PIDDOK L. Contribution of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob Agents Chemother 1996; 40: 2380-6.
5. DEGUCHI K, FUKUOKA A, YASUDA M, NAKANO S, KANEMATSU E, NISHINO Y ET AL. Alterations in the GyrA subunit of DNA Gyrase and the ParC subunit of Topoisomerase IV in quinolone-resistant clinical isolates of K. pneumoniae. Antimicrob Agents Chemother 1997; 41: 699-701.
6. VILA J, RUIZ J, GOÑI P, MARCOS M, JIMÉNEZ DE ANTA M. Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 1995; 39: 1201-3.
7. HIGGINS P, FLUIT A, MILATOVIC D, VERHOEF J, SHMITZ F. Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa. Int J Antimicrob Agents 2003; 21: 409-13.
8. BROWN S, AMYES S. Quinolone Resistance. In: Methods in Molecular Medicine. New Jersey: Editorial Humana Press Inc. 1998; 617-39.
9. KOMP P, KARLSSON S, HUGHES D. Mutation Rate and Evolution of Fluoroquinolone Resistance in Escherichia coli Isolates from Patients with Urinary Tract Infections. Antimicrob Agents Chemother 2003; 47: 3222-32.
10. AKASAKA T, TANAKA M, YAMAGUCHI A, SATO K. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob Agents Chemother 2001; 45: 2263-8.
11. th Edition. NCCLS document M2-A7. NCCLS, Wayne, Pennsylvania, USA.
12. th Edition. NCCLS document M7-A5. NCCLS, Wayne, Pennsylvania, USA.
13. REYES A, BELLO H, DOMÍNGUEZ M, MELLA S, ZEMELMAN R, GONZÁLEZ G. Prevalence and types of class 1 integrons in aminoglycoside-resistant Enterobacteriaceae from several Chilean hospitals. J Antimicrob Chemother 2003; 51: 317-21.
14. WEIGEL L, STEWARD C, TENOVER F. gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae. Antimicrob Agents Chemother 1998; 42: 2661-7.
15. JACOBY G. Mechanisms of Resistance to Quinolones. Clin Infect Dis 2005; 41: S120-126.
16. CHEN F, LO H. Molecular mechanisms of fluoroquinolone resistance. J Microbiol Immunol Infect 2003; 36: 1-9.
17. KUREISHI A, DIVER M, BECKTHOLD B, SCHOLLAARDT T, BRYAN L. Cloning and nucleotide sequence of Pseudomonas aeuriginosa PAO1 and quinoloneresistant clinical isolates. Antimicrob Agents Chemother 1994; 38: 1944-52.
18. SWANBERG S, WANG J. Cloning and sequencing of the Escherichia coli gyrA gene coding for the A subunit of DNA gyrase. J Mol Biol 1987; 197: 729-36.
19. BRISSE S, MILATOVIC D, FLUIT A, VERIIOEF J, MARTIN N, SCHEURING S ET AL. Comparative in vitro activities of Ciprofloxacin, Clinafloxacin, Gatifloxacin, Levofloxacin, Moxifloxacin, and Trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogens. Clinical isolates with alterations in GyrA and ParC Proteins. Antimicrob Agents Chemother 1999; 43 2051-5.
20. KYU J, SEON Y, KEUN Y, SU B. Mutations in the gyrA and parC Genes in Ciprofloxacin-Resistant Clinical Isolates of Acinetobacter baumannii in Korea. Microbiol Immunol 2005: 647-53.
21. VILA J, RUIZ J, GOÑI P, JIMÉNEZ T. Quinoloneresistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii. J Antimicrob Chemother 1997; 39: 757-62.
22. YUNEZAWA M, TAKAHATA M, MATSUNARA N, WATANABE Y, NARITA H. DNA Gyrase gyrA mutations in Quinolone-Resistant Clinical Isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995; 39: 1970-2.
23. HEDDLE J, MAXWELL A. Quinolone-binding pocket of DNA gyrase: role of gyrB. Antimicrob Agents Chemother 2002; 46: 1805-15.
24. OTEO J, CAMPOS J. Uso de quinolonas y resistencia. Enferm Infecc Microbiol Clin 2004; 22: 201-3.
25. MARTÍNEZ J, ALONSO A, GÓMEZ- GÓMEZ J, BAQUERO F. Quinolone resistance by mutations in chromosomal gyrase genes. Just the tip of the iceberg? J Antimicrob Chemother 1998; 42: 683-8.
26. GARCÍA P. Resistencia bacteriana en Chile. Rev Chil Infect 2003; 20: S11-S23.